Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab

Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab

Abstract Background Giant cell tumor of bone (GCTB) is a rare osteoclastogenic stromal tumor. GCTB can rarely undergo malignant transformation. This post hoc analysis evaluated and classified malignancies in patients with GCTB who received denosumab. Methods This analysis was conducted on patients w...

Full description

Bibliographic Details
Main Authors: Emanuela Palmerini, Leanne L. Seeger, Marco Gambarotti, Alberto Righi, Peter Reichardt, Susan Bukata, Jean-Yves Blay, Tian Dai, Danielle Jandial, Piero Picci
Format: Article
Language:English
Published: BMC 2021-01-01
Series:BMC Cancer
Subjects:
Denosumab
Giant cell tumor of bone
Bone neoplasms
RANK ligand
Online Access:https://doi.org/10.1186/s12885-020-07739-8

Internet

https://doi.org/10.1186/s12885-020-07739-8

Similar Items